Why do pharma and biotech companies collaborate with Talisman?

Talisman combines deep insights into neurodegenerative disease biology, cutting edge stem-cell biology technologies and broad wet lab capabilities. We bring this unique skill-set to our bespoke collaborative projects, providing our external collaborators with a step-change in their R&D program. Our collaborators do not come to us with fully-formed projects – they come to us with challenging research and development questions and we work together to plan how to solve those challenges rapidly and effectively, in a way that fits their requirements.

Since Talisman was founded in 2014, collaborators have benefited from:

• Rapid insights into validation of candidate novel therapies using human cell-based systems
• Avoidance of costly, unnecessary and potentially non-translatable animal studies, with human stem cell-based disease models providing key data
• Access to world leading experts in neurobiology, neurodegeneration and stem cell science, without the need to build an in-house team, re-train existing teams or build specialist in-house labs